Q1 2024 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Lifted by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Research analysts at Leerink Partnrs lifted their Q1 2024 earnings per share (EPS) estimates for Neurocrine Biosciences in a research note issued on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $0.67 per share for the quarter, up from their previous forecast of $0.64. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.83 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences’ Q2 2024 earnings at $1.26 EPS, Q3 2024 earnings at $1.41 EPS, Q4 2024 earnings at $1.46 EPS, FY2024 earnings at $4.80 EPS, FY2025 earnings at $6.65 EPS, FY2026 earnings at $9.15 EPS, FY2027 earnings at $10.80 EPS and FY2028 earnings at $12.25 EPS.

NBIX has been the subject of several other research reports. Barclays upped their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Citigroup reduced their target price on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating for the company in a research note on Thursday, February 8th. Wells Fargo & Company boosted their price target on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 8th. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Finally, The Goldman Sachs Group boosted their target price on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Six equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $139.25.

Neurocrine Biosciences Trading Down 0.6 %

Neurocrine Biosciences stock opened at $138.09 on Thursday. The stock has a 50 day moving average of $136.96 and a two-hundred day moving average of $126.05. Neurocrine Biosciences has a twelve month low of $89.04 and a twelve month high of $148.37. The stock has a market capitalization of $13.74 billion, a price-to-earnings ratio of 57.06, a PEG ratio of 0.90 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. During the same period in the prior year, the company earned $0.88 earnings per share. The business’s revenue was up 25.0% compared to the same quarter last year.

Insider Buying and Selling

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 2,707 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total transaction of $380,847.83. Following the sale, the chief executive officer now owns 502,188 shares in the company, valued at approximately $70,652,829.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total transaction of $380,847.83. Following the transaction, the chief executive officer now owns 502,188 shares of the company’s stock, valued at $70,652,829.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Darin Lippoldt sold 10,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $139.86, for a total transaction of $1,398,600.00. Following the completion of the sale, the insider now directly owns 35,882 shares of the company’s stock, valued at $5,018,456.52. The disclosure for this sale can be found here. Insiders sold 177,176 shares of company stock worth $24,562,081 in the last ninety days. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Dodge & Cox raised its stake in shares of Neurocrine Biosciences by 489.8% during the fourth quarter. Dodge & Cox now owns 1,259,744 shares of the company’s stock valued at $165,984,000 after purchasing an additional 1,046,142 shares during the period. Norges Bank acquired a new stake in Neurocrine Biosciences during the fourth quarter valued at approximately $111,786,000. BlackRock Inc. lifted its holdings in Neurocrine Biosciences by 6.6% during the 1st quarter. BlackRock Inc. now owns 13,466,650 shares of the company’s stock worth $1,363,094,000 after buying an additional 838,997 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $105,408,000. Finally, Braidwell LP bought a new stake in shares of Neurocrine Biosciences during the 1st quarter valued at about $77,615,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.